Earnings Feed
Start Free
GUIDED THERAPEUTICS INC·4

Mar 12, 7:52 PM ET

Imhoff John E 4

4 · GUIDED THERAPEUTICS INC · Filed Mar 12, 2026

Research Summary

AI-generated summary of this filing

Updated

Guided Therapeutics (GTHP) 10% Owner John Imhoff Acquires Shares

What Happened

  • John E. Imhoff, a reported 10% owner of Guided Therapeutics (GTHP), acquired approximately 1,589,604 common shares across several transactions between Dec 18, 2025 and Feb 27, 2026. Key components:
    • Converted convertible promissory note balances into common stock: 195,460 shares (Dec 18, 2025) for $13,682.19; 312,720 shares (Feb 2, 2026) for $21,890.41; and 156,086 shares (Feb 26, 2026) for $10,926.03 — all at $0.07 per share (total ≈ $46,498.63).
    • Exercised warrants (exchanged then exercised) resulting in 500,000 shares upon payment of $100,000.
    • Converted 100 shares of Series E preferred into 400,000 common shares (Feb 27, 2026).
    • Received 25,338 shares as payment of accrued dividends on Series E preferred (issued at a conversion price of $0.3157).
  • These were net acquisitions (not open‑market purchases) largely resulting from conversions, dividend settlement in shares, and a warrant exercise — i.e., financing and conversion activity rather than typical buy/sell market trades.

Key Details

  • Transaction dates and material prices:
    • 12/18/2025: 195,460 shares converted at $0.07 (≈ $13,682).
    • 02/02/2026: 312,720 shares converted at $0.07 (≈ $21,890).
    • 02/26/2026: 156,086 shares converted at $0.07 (≈ $10,926).
    • 02/25/2026: 500,000 warrants exchanged/issued at $0.20 then exercised for $100,000 (per filing).
    • 02/27/2026: 100 Series E preferred shares converted into 400,000 common shares.
    • 01/05/2026: 25,338 shares issued for accrued dividends (conversion price $0.3157).
  • Cash paid (reported): ≈ $46,499 for note conversions + $100,000 for warrant exercise.
  • Remaining convertible note principal after conversions: $120,000 outstanding under the September 25, 2025 note (per footnotes).
  • Notable footnotes:
    • Conversions were of a Sept. 25, 2025 convertible promissory note (principal + accrued interest converted at $0.07; balance partially remains and may convert at variable price upon default).
    • Warrants were exchanged (exercise-price changes and one warrant expiration extended to 9/1/2027) before exercise.
    • 25,338 shares were issued as dividend payment on Series E preferred.
  • Shares beneficially owned after these transactions are not specified in the provided summary of the filing.

Context

  • These transactions are largely corporate-financing/convertible-instrument related (debt-to-equity conversions, dividend-in‑stock settlement, warrant exercise) rather than open-market purchases or gifts. Such activity often reflects capital-raising or restructuring actions rather than direct market-timing by the insider.
  • As a 10% owner, Imhoff’s transactions are reported under insider rules; they are informative about capital structure changes but do not by themselves indicate personal bullish/sell intent.
  • The filing documents conversion mechanics and warrant-exchange details; several derivative instruments were converted or exchanged as part of the transactions.

Insider Transaction Report

Form 4
Period: 2025-12-18
GUIDED THERAPEUTICS INCGTHP
Imhoff John E
Director10% Owner
Transactions
  • Conversion

    Common Stock

    [F1]
    2025-12-18$0.07/sh+195,460$13,682→ 19,658,955 total
  • Other

    Common Stock

    [F2]
    2026-01-05+25,338→ 19,684,293 total
  • Conversion

    Common Stock

    [F3]
    2026-02-02$0.07/sh+312,720$21,890→ 19,997,013 total
  • Exercise of In-Money

    Common Stock

    [F4]
    2026-02-25+500,000→ 20,497,013 total
  • Other

    Preferred Series E Stock

    [F5]
    2026-02-27−100→ 0 total
  • Other

    Common Stock

    [F5]
    2026-02-27+400,000→ 20,897,013 total
  • Conversion

    Common Stock

    [F6]
    2026-02-27$0.07/sh+156,086$10,926→ 21,053,099 total
  • Conversion

    Convertible Promissory Note

    [F1]
    2025-12-18−195,460→ 150,000 total
    Exercise: $0.07From: 2025-11-28Exp: 2027-02-28→ Common Stock (195,460 underlying)
  • Conversion

    Convertible Promissory Note

    [F3]
    2026-02-02−312,720→ 130,000 total
    Exercise: $0.07From: 2026-01-30Exp: 2027-02-28→ Common Stock (312,720 underlying)
  • Other

    Warrants

    [F4]
    2026-02-25−500,000→ 0 total
    Exercise: $0.65From: 2022-09-01Exp: 2026-09-01→ Common Stock (500,000 underlying)
  • Other

    Warrants

    [F4]
    2026-02-25+500,000→ 500,000 total
    Exercise: $0.65From: 2026-02-25Exp: 2027-09-01→ Common Stock (500,000 underlying)
  • Other

    Warrants

    [F4]
    2026-02-25−500,000→ 0 total
    Exercise: $0.50From: 2022-09-01Exp: 2026-09-01→ Common Stock (500,000 underlying)
  • Other

    Warrants

    [F4]
    2026-02-25+500,000→ 500,000 total
    Exercise: $0.20From: 2026-02-25Exp: 2026-02-25→ Common Stock (500,000 underlying)
  • Exercise of In-Money

    Warrants

    [F4]
    2026-02-25−500,000→ 0 total
    Exercise: $0.20From: 2026-02-25Exp: 2026-02-25→ Common Stock (500,000 underlying)
  • Conversion

    Convertible Promissory Note

    [F6]
    2026-02-27$0.07/sh−156,086$10,926→ 120,000 total
    Exercise: $0.07From: 2026-02-27Exp: 2027-02-28→ Common Stock (156,086 underlying)
Footnotes (6)
  • [F1]On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.
  • [F2]These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.3157.
  • [F3]On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.
  • [F4]During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027.
  • [F5]On February 27, 2026, Mr. Imhoff converted 100 shares of Series E preferred stock into 400,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price.
  • [F6]On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.
Signature
/s/ John E. Imhoff|2026-03-12

Documents

1 file
  • 4
    form4.xmlPrimary

    FORM 4